RR
Reena Ray
About Reena Ray
Data last updated:
Reena Ray has 13 years in corporate governance. Holds Director role. Currently with 2 companies, including Medirays Pharma Private Limited and Leefordian Pharmaceuticals Private Limited. Formerly with 1 company. Engaged in General Business, Technology. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Abpl Arina Biotech Private Limited U21002DL2026PTC469322 | Director | 06 Aug 2026 | 2026 | – | Active |
| Leefordian Pharmaceuticals Private Limited U51507CT2014PTC001506 | Director | 15 Sep 2014 | 2014 | – | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Medirays Pharma Private Limited U51909DL2013PTC254726 | Director | 02 Jul 2013 | 2013 | – | Strike Off |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Reena Ray
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Reena Ray
Reena Ray has 13 years in corporate governance. Holds Director role. Currently with 2 companies, including Medirays Pharma Private Limited and Leefordian Pharmaceuticals Private Limited. Formerly with 1 company. Engaged in General Business, Technology. Contributes to corporate operations.
Reena Ray is associated with 2 companies as Director, including Abpl Arina Biotech Private Limited, Leefordian Pharmaceuticals Private Limited.
Reena Ray has expertise in General Business, Technology.
Reena Ray has 13 years in corporate governance.
Reena Ray currently holds positions at 2 companies: Abpl Arina Biotech Private Limited, Leefordian Pharmaceuticals Private Limited.